Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation

This publication has 67 references indexed in Scilit:

• Targeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma
  Clinical Cancer Research, 2006
• Protein farnesylation: Implications for normal physiology, malignant transformation, and cancer therapy
  Cancer Cell, 2005
• Therapy Insight: potential of statins for cancer chemoprevention and therapy
  Nature Clinical Practice Oncology, 2005
• Simvastatin inhibits T‐cell activation by selectively impairing the function of Ras superfamily GTPases
  The FASEB Journal, 2005
• The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion–mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase
  Blood, 2004
• Targeting RAS signalling pathways in cancer therapy
  Nature Reviews Cancer, 2003
• Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response
  Oncogene, 2002
• HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis
  Leukemia, 2002
• Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)
  Oncogene, 2002
• Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
  Nature, 1994